ClinicalTrials.gg
CompletedNCT03584919Updated Jul 12, 2018

Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans

An interventional study of doxycycline and Cefuroxime Axetil 500Mg Tab in Erythema Chronicum Migrans, sponsored by University Medical Centre Ljubljana. Completed. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 12 years after the study started (first participant enrolled Jun 2006, registered Jun 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
509
Allocation
Non-randomized
Ages
15 Years and older
Sex
All
01

Study summary

A European, prospective clinical trial in which doxycycline and cefuroxime axetil were compared in the treatment of adult patients with erythema migrans included a control group to address this question. Evaluations of patients were conducted at baseline, 14 days and 2, 6, and 12 months after enrollment. Control subjects were evaluated at baseline and at 6 and 12 months. Subjective complaints that newly developed or intensified since the onset of erythema migrans or since the date of enrollment for controls were referred to as "new or increased symptoms"(NOIS).

02

Conditions studied

  • Erythema Chronicum Migrans
03

In context

Lead sponsor

University Medical Centre Ljubljana is the lead sponsor of 296 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • typical solitary erythema migrans as defined by the United States Centers for Disease Control and Prevention. In addition, patients with skin lesion \<5 cm in diameter were also included if they recalled a recent tick bite at the site of the skin lesion, had a symptom-free interval between the bite and the onset of the lesion, and reported an expanding skin lesion prior to diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Lyme disease previously
  • pregnancy or lactation
  • serious adverse reaction to a beta-lactam or tetracycline drug in the past
  • received an antibiotic with known anti-borrelial activity within 10 days
  • multiple erythema migrans lesions
  • presence of an extracutaneous manifestation of Lyme disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
509 participants

Study arms

  • Active comparator
    EM doxycycline

    patients with EM who received doxycycline

    Drug: doxycycline

  • Active comparator
    EM cefuroxime axetil

    patients with EM who received cefuroxime axetil

    Drug: Cefuroxime Axetil 500Mg Tab

  • Placebo comparator
    controls

    control subjects without history of Lyme disease

    Other: control subjects

Interventions

  • patients received oral doxycycline 100 milgrams bid for 15 days

  • patients received cefuroxime axetil 500 milgrams bid for 15 days

  • Othercontrol subjects

    no intervention

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Objective Manifestations and Subjective New or Increased Symptoms (NOIS) in Patients Treated for Erythema Migrans With Doxycycline or Cefuroxime Axetil for 15 Days

    At each visit patients were examined and asked about the presence of any symptoms that newly developed or had worsened since erythema migrans. If such symptoms had no other medical explanation they were regarded as new or increased symptoms (NOIS). Complete response was defined as absence of any manifestations of Lyme borreliosis, with return to pre-Lyme borreliosis health status. Partial response was defined as presence of NOIS. Failure was defined as presence of objective manifestations of Lyme borreliosis or persistence of Borrelia burgdorferi sensu lato in skin at the site of the previous erythema migrans.

    Time frame: One year follow-up (follow-up time points at 14 days, 2 months, 6 months, and 12 months after enrolment)

Secondary outcomes

  1. Number of Patients (at 12 Months After Treatment With Doxycycline or Cefuroxime Axetil for 15 Days for Erythema Migrans) and Number of Control Subjects (Without a History of Lyme Borreliosis) With Nonspecific Symptoms.

    12 months after treatment patients and controls were asked to complete a written questionnaire asking whether they had had any of 8 nonspecific symptoms (fatigue, arthralgias, headache, myalgias, paresthesias, concentration difficulties, or irritability) within the preceding week. For both patients and controls, the severity of each individual symptom was graded by the subject on a 10-cm visual analog scale (10 = most severe).

    Time frame: 12 months after treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Veluscek M, Bajrovic FF, Strle F, Stupica D. Doxycycline-induced photosensitivity in patients treated for erythema migrans. BMC Infect Dis. 2018 Aug 3;18(1):365. doi: 10.1186/s12879-018-3270-y. PubMed 30075748 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03584919
Responsible party
Daša Stupica (Principal Investigator, University Medical Centre Ljubljana) — Principal investigator
First posted
Jul 12, 2018
Start date
Jun 1, 2006
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update
Jul 12, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxycycline · Cefuroxime axetil

Start the discussion